Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin
| Autor: | David R. Snydman, T Hougen, H. C. Meissner, Robert L. Geggel, Gerald R. Marx, J R Groothuis, V G Hemming, David Fulton |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
Paramyxoviridae
medicine.medical_treatment Premedication Respirovirus Infections Virus Infant Newborn Diseases Risk Factors medicine Humans Pharmacology (medical) Infusions Intravenous Respiratory Tract Infections Pharmacology biology business.industry Respiratory disease Antibody titer Infant Newborn Immunoglobulins Intravenous Infant Immunotherapy biology.organism_classification medicine.disease Immunoglobulin A Respiratory Syncytial Viruses Infectious Diseases Bronchopulmonary dysplasia Immunology biology.protein Respiratory virus Antibody business Research Article |
| Zdroj: | Scopus-Elsevier |
| ISSN: | 0066-4804 |
| Popis: | We performed a randomized, controlled trial of intravenous immune globulin (respiratory syncytial virus [RSV] neutralizing [Nt] antibody titer of 1:950 in 5% solution) to evaluate protection against RSV-induced disease over two respiratory virus seasons. Forty-nine children (mean age at enrollment, 4.5 months) with severe congenital heart disease or bronchopulmonary dysplasia were randomized as follows. Twenty-four patients were followed as controls and received no immune globulin. Twenty-five patients received monthly infusions of immune globulin at a dose of 500 mg/kg of body weight. There was a similar distribution between groups of patients with heart disease and bronchopulmonary dysplasia. There were 12 culture-proven RSV infections, 6 in the prophylaxis group and 6 in the control group. There was a trend toward less severe RSV illness in immune globulin recipients, as measured by length of hospitalization. Four of the six immune globulin recipients were hospitalized for a total of 35 days (mean, 8.8 +/- 5.0 days) because of RSV illness, in contrast to 51 hospital days (mean, 12.8 +/- 7.6 days) among RSV-infected controls. We conclude that monthly infusions of standard immune globulin containing RSV Nt antibodies may be safely administered to high-risk children, but that standard intravenous immune globulin does not contain sufficient RSV Nt antibody titer to fully protect against severe RSV illness. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|